A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Age ≥ 18 years - BMI ≥ 30 kg/m2 at screening - diagnosis of heart failure - NYHA Class II-IV - left ventricular ejection fraction of of at least 40% - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- Type 1 diabetes - acute or chronic hepatitis - history of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior, any prior suicide attempt, or history of self injury in past 5 years - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:
Drug: Maridebart cafraglutide, Drug: Placebo
Conditions:
Heart & Vascular
Keywords:
body mass index (BMI) 30 kg/m2, Clinics and Surgery Center (CSC), heart failure (HF) with preserved or mildly reduced EF, obesity

More Information

Description: This study is being done to learn more about maridebart cafraglutide (MariTide [formerly AMG 133]) for people with heart failure (HF) and obesity in addition to their routine medical care. Participants will receive treatment with either MariTide or a placebo, which will be called a study drug. A placebo looks the same as the investigational medicine but contains no actual medicine.
Study Contact: Gretchen Peichel - gpeichel@umn.edu
Principal Investigator: Tamas Alexy
Phase: PHASE3
IRB Number: STUDY00026740